Academic Journal
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
| العنوان: | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial |
|---|---|
| المؤلفون: | Beije, N. (Nick), Kraan, J., Taal, W. (Walter), Holt, B. (Bronno) van der, Oosterkamp, H.M. (Hendrika M), Walenkamp, A.M.E. (Annemiek M.), Beerepoot, L.V. (Laurens), Hanse, M.C.J., Van Linde, M.E., Otten, A., Vernhout, R. (Rene), Vos, F.Y.F.L. de, Gratama, J.W. (Jan-Willem), Sleijfer, S. (Stefan), Bent, M.J. (Martin) van den |
| المصدر: | British Journal of Cancer vol. 113 no. 2, pp. 226-231 |
| سنة النشر: | 2015 |
| المجموعة: | RePub - Publications from Erasmus University, Rotterdam |
| الوصف: | Background:Angiogenesis is crucial for glioblastoma growth, and anti-vascular endothelial growth factor agents are widely used in recurrent glioblastoma patients. The number of circulating endothelial cells (CECs) is a surrogate marker for endothelial damage. We assessed their kinetics and explored their prognostic value in patients with recurrent glioblastoma.Methods:In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine. Before treatment, after 4 weeks and after 6 weeks of treatment, CECs were enumerated.Results:The number of CECs increased during treatment with bevacizumab plus lomustine, but not during treatment in the single-agent arms. In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log 10 CEC hazard ratio (HR) 0.41, 95% CI 0.18-0.91) and 6 weeks (log 10 CEC HR 0.16, 95% CI 0.05-0.56) of treatment were associated with improved overall survival (OS). Absolute CEC numbers in patients receiving bevacizumab plus lomustine or bevacizumab single agent were not associated with |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | http://repub.eur.nl/pub/81045; urn:hdl:1765/81045 |
| DOI: | 10.1038/bjc.2015.191 |
| الاتاحة: | http://repub.eur.nl/pub/81045 https://doi.org/10.1038/bjc.2015.191 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.AD2750B4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bjc.2015.191 |
|---|